Daniel S. Lynch joined SpringWorks Therapeutics at launch in 2017 and is currently chairman of the board of directors. Since October 2007, Dan has served as executive chairman or board member for a number of private biopharmaceutical companies, including Stromedix (until its acquisition by Biogen Idec in February 2012), Translate Bio, Nimbus Discovery, Edimer Pharmaceuticals, Ember Therapeutics, Blueprint Medicines, and Sesen Bio. He also served on the board of directors of BIND Biosciences. Previously, Dan served as chief executive and chief financial officer of ImClone Systems Corporation, or ImClone. As ImClone’s chief executive officer, he led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX (cetuximab), a novel cancer treatment. As its chief financial officer, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, Dan served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology for five years until December 2010, when it was acquired by McKesson.
Dan received his B.A. in mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.
Chief Financial Officer, Amplyx Pharmaceuticals, Inc.
Alan Fuhrman is a member of the Board of Directors for Checkmate Pharmaceuticals. Alan served on the Board of Directors and as Chair of the Audit Committee for Loxo Oncology until its sale to Eli Lilly in the first quarter of 2019. He currently serves as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. Prior to joining Amplyx, he served as CFO of Mirna Therapeutics, a publicly traded, clinical-stage microRNA company that merged with Synlogic in August 2017. Alan previously served as CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. Earlier in his career, Alan practiced as a certified public accountant with Coopers & Lybrand. Alan received a B.S. in both Business Administration and Agricultural Economics from Montana State University.
Saqib Islam, J.D.
Chief Executive Officer
Saqib Islam was appointed chief executive officer of SpringWorks Therapeutics in 2018. He was a founding member of the company’s executive team since its launch in 2017 and previously served as chief financial officer and chief business officer. Prior to joining SpringWorks Therapeutics, Saqib was chief business officer at Moderna Therapeutics, where he oversaw critical aspects of the company’s growth, including global strategic planning, corporate development and business development. Prior to joining Moderna, Saqib served as executive vice president, chief strategy and portfolio officer at Alexion Pharmaceuticals, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Saqib has over 25 years of international business management experience and an extensive background in the healthcare banking sector, having held managing director positions in the investment banking divisions of Morgan Stanley and Credit Suisse Securities.
Saqib received his bachelor’s degree from McGill University, graduating as a Faculty and University Scholar, and a J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar.
Freda Lewis-Hall, M.D., DFAPA
Executive Vice President, Pfizer Inc
Freda Lewis-Hall is an executive vice president at Pfizer and serves as the company’s chief patient officer. In this role, Freda is working to extend the reach of Pfizer’s patient-facing health information and education and amplify the voice of the patient inside and outside Pfizer. From 2009-2018 Freda served as Pfizer’s chief medical officer, responsible for the safe, effective and appropriate use of Pfizer medicines and vaccines, and in this role she reshaped Pfizer’s medical policies and practices to intensify the company’s focus on patient engagement and inclusion.
Before joining Pfizer, Freda held senior leadership positions in medical affairs and product development with Vertex, Bristol-Myers Squibb, Pharmacia and Eli Lilly and Company. Prior to joining the biopharmaceutical industry, she served as vice chairperson and associate professor in the Department of Psychiatry at Howard University College of Medicine and was an advisor to the National Institute of Mental Health. She graduated from Johns Hopkins and earned her medical doctorate at Howard University College of Medicine. She launched her medical career as a practicing physician and then focused her academic research on the effects of health care disparities and the impact of mental illness on families and communities.
Freda is a distinguished fellow of the American Psychiatric Association. She is a frequent speaker on issues such as improving patient safety and outcomes and reducing stigma and healthcare disparities. She appears regularly on health-related television programs in major global markets, including CBS-syndicated shows such as The Doctors and Dr. Phil. She also shares health and medical information through gethealthystayhealthy.com.
Managing Director, Bain Capital Life Sciences
Jeffrey Schwartz is a managing director of Bain Capital Life Sciences, where he is a founding member of the team. Prior to founding Bain Capital Life Sciences in 2016, he was a leader within the healthcare vertical of Bain Capital Private Equity. Since joining the firm, Jeffrey has been actively involved in and served on the board of directors for a wide spectrum of healthcare companies in which Bain Capital Private Equity has made investments including: Air Medical Group Holdings, Beacon Health Options, CRC Health, HCA, Lake Region Medical, Quintiles, QuVa Pharma and Warner Chilcott. Prior to joining Bain Capital, Jeffrey served as an equity research analyst at Lehman Brothers, working in both New York and London.
Jeffrey received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Yale University with a B.A. in economics.
Stephen Squinto, Ph.D.
Venture Partner, OrbiMed
Stephen Squinto, Ph.D., joined SpringWorks Therapeutics at launch in 2017 and is acting head of research and development. Steve is a venture partner with OrbiMed who brings over 25 years of biotechnology industry experience. Steve was a co-founder of Alexion Pharmaceuticals and recently served as its executive vice president and chief global operations officer. Prior to 2013, he was Alexion’s global head of research and development. From 1988 to 1992, Steve held various positions at Regeneron Pharmaceuticals. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Steve received his B.A. in chemistry and Ph.D. in biochemistry and biophysics from Loyola University of Chicago.